Drug information for CEREBYX
Form
Dosage
Status
Therapeutic Equivalence
Active Ingred
Ref.
Sponsor
Document
INJECTABLE; INJECTION
EQ 50MG PHENYTOIN NA/ML
Discontinued
FOSPHENYTOIN SODIUM
fosphenytoin
PARKE DAVIS
20450
2011-11-17 Letter
2011-11-17 Letter
2011-11-17 Letter
2011-11-17 Letter
2011-11-16 Label
2011-11-16 Label
2011-11-16 Label
2011-11-16 Label
2007-05-30 Review
2007-05-29 Review
2003-06-17 Review
2003-04-25 Label
2001-08-31 Label
Drug Adverse Effects information for CEREBYX
Role code
Indications
Reaction
# Reports
PS
CONVULSION
AMNESIA
2
PS
CONVULSION
BLISTER
2
PS
CONVULSION
FINGER AMPUTATION
2
PS
CONVULSION
SCAR
2
PS
CONVULSION
SKIN NECROSIS
2
PS
CONVULSION
SOFT TISSUE NECROSIS
2
PS
CONVULSION
STEVENS-JOHNSON SYNDROME
2
PS
CONVULSION
TOXIC EPIDERMAL NECROLYSIS
2
C
BRONCHIAL OEDEMA
LYMPHOCYTE COUNT DECREASED
1
C
CONSTIPATION
STEVENS-JOHNSON SYNDROME
1
C
CONVULSION
LYMPHOCYTE COUNT DECREASED
1
C
CONVULSION
STEVENS-JOHNSON SYNDROME
1
C
COUGH
STEVENS-JOHNSON SYNDROME
2
C
DIARRHOEA
STEVENS-JOHNSON SYNDROME
1
C
DYSPEPSIA
STEVENS-JOHNSON SYNDROME
1
C
DYSPNOEA
LYMPHOCYTE COUNT DECREASED
1
C
HEADACHE
STEVENS-JOHNSON SYNDROME
1
C
INFECTION PROPHYLAXIS
LYMPHOCYTE COUNT DECREASED
2
C
NAUSEA
STEVENS-JOHNSON SYNDROME
3
C
PAIN
STEVENS-JOHNSON SYNDROME
5
C
PROPHYLAXIS
LYMPHOCYTE COUNT DECREASED
1
C
PROPHYLAXIS AGAINST GASTROINTESTINAL ULCER
LYMPHOCYTE COUNT DECREASED
1
C
PRURITUS
STEVENS-JOHNSON SYNDROME
1
C
PYREXIA
LYMPHOCYTE COUNT DECREASED
1
C
SLEEP DISORDER
STEVENS-JOHNSON SYNDROME
2
C
URTICARIA
STEVENS-JOHNSON SYNDROME
1
Ads by Google